<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01637636</url>
  </required_header>
  <id_info>
    <org_study_id>VP-VEC-162-1112</org_study_id>
    <nct_id>NCT01637636</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.</brief_title>
  <official_title>An Open-label, Single-sequence Study in Two Cohorts of Healthy Subjects to Evaluate the Single-dose Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to understand whether there is any difference in the&#xD;
      amount of tasimelteon (including its breakdown product) in the blood when taken alone and in&#xD;
      combination with either rifampin or ketoconazole.&#xD;
&#xD;
      Cytochrome P450 3A4 is an important enzyme produced by the body to breakdown certain&#xD;
      medications. In this study, the effect that this important enzyme has on tasimelteon is being&#xD;
      studied by assessing the effect rifampin and ketoconazole have on tasimelteon and how they&#xD;
      are broken down by your body. Rifampin is a known inducer of Cytochrome P450 3A4 enzyme&#xD;
      meaning that it increases the activity of the enzyme. Ketoconazole is a known inhibitor of&#xD;
      Cytochrome P450 3A4 enzyme meaning that it decreases the activity of the enzyme.&#xD;
&#xD;
      In addition, the safety and tolerability of tasimelteon will also be assessed throughout the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of tasimelteon and tasimelteon's metabolites with and without the CYP3A4 inhibitor ketoconazole.</measure>
    <time_frame>Day 1: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose. Days 6 and 7: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of tasimelteon and tasimelteon's metabolites with and without the CYP3A4 inducer rifampin.</measure>
    <time_frame>Day 1: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose. Days 12 and 13: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Rifampin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketoconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tasimelteon</intervention_name>
    <description>20mg, oral capsule, once, Days 1 and 12</description>
    <arm_group_label>Rifampin</arm_group_label>
    <other_name>VEC-162, BMS-214778</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tasimelteon</intervention_name>
    <description>20mg, oral capsule, once, Days 1 and 6</description>
    <arm_group_label>Ketoconazole</arm_group_label>
    <other_name>VEC-162, BMS-214778</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11</description>
    <arm_group_label>Rifampin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6</description>
    <arm_group_label>Ketoconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women ages 18 - 55 years, inclusive;&#xD;
&#xD;
          2. Non-smokers;&#xD;
&#xD;
          3. Subjects with Body Mass Index (BMI) of ≥18 and ≤35 kg/m^2;&#xD;
&#xD;
          4. Males, non-fecund females, or females of child-bearing potential using an acceptable&#xD;
             method of birth control for a period of 35 days before the first dosing;&#xD;
&#xD;
          5. Vital signs which are within the ranges shown below:&#xD;
&#xD;
               1. Body temperature between 35.0-37.5 °C;&#xD;
&#xD;
               2. Systolic blood pressure between 90-150 mmHg;&#xD;
&#xD;
               3. Diastolic blood pressure between 50-95 mmHg;&#xD;
&#xD;
               4. Pulse rate between 50-100 bpm.&#xD;
&#xD;
          6. Ability and acceptance to provide written informed consent;&#xD;
&#xD;
          7. Willing and able to comply with study requirements and restrictions;&#xD;
&#xD;
          8. In good health as determined by past medical history, physical examination,&#xD;
             electrocardiogram, clinical laboratory tests and urinalysis;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of recent (within six months) drug or alcohol abuse;&#xD;
&#xD;
          2. Any major surgery within three months of Baseline or any minor surgery within one&#xD;
             month;&#xD;
&#xD;
          3. History or current evidence of cardiovascular, hepatic, hematopoietic, renal,&#xD;
             gastrointestinal or metabolic dysfunction or psychiatric disease judged by the&#xD;
             Investigator to be clinically significant;&#xD;
&#xD;
          4. History (including family history) or current evidence of congenital long QT syndrome&#xD;
             or known acquired QT interval prolongation;&#xD;
&#xD;
          5. Subjects who are currently considered a suicide risk, any subject who has ever made a&#xD;
             suicide attempt, or those who are currently demonstrating active (within the past 6&#xD;
             months) suicidal ideation;&#xD;
&#xD;
          6. Any condition requiring the regular use of medication except those listed in Section&#xD;
             8.2 of the protocol;&#xD;
&#xD;
          7. Exposure to any investigational drug, including placebo, within 30 days or 5&#xD;
             half-lives (whichever is longer) of baseline&#xD;
&#xD;
          8. Exposure (within 2 weeks of the Baseline Visit) to any over-the-counter medications&#xD;
             including melatonin, dietary supplements and/or herbal remedies, except those listed&#xD;
             on Section 8.2;&#xD;
&#xD;
          9. Treatment with any drug known to cause major organ system toxicity (e.g.,&#xD;
             chloramphenicol or tamoxifen) during the 60 days preceding the Screening visit;&#xD;
&#xD;
         10. History of intolerance and/or hypersensitivity to ketaconazole, drugs similar to&#xD;
             ketoconazole (e.g. miconzaole or fluconazole), rifampin, tasimelteon, and/or drugs&#xD;
             similar to tasimelteon including melatonin;&#xD;
&#xD;
         11. Donation or loss of 400 mL or more of blood within one month prior to the Baseline&#xD;
             Visit;&#xD;
&#xD;
         12. Significant illness within the two weeks prior to Baseline;&#xD;
&#xD;
         13. Pregnant or lactating females;&#xD;
&#xD;
         14. History of porphyria or liver disease and/or positive for one or more of the following&#xD;
             serological results:&#xD;
&#xD;
               1. A positive hepatitis C antibody test (anti-HCV)&#xD;
&#xD;
               2. A positive hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
               3. A positive HIV test result&#xD;
&#xD;
         15. Participation in a previous BMS-214778/VEC-162 trial;&#xD;
&#xD;
         16. Use of any food or beverage containing grapefruit or grapefruit juice, apple or orange&#xD;
             juice, vegetables from the mustard green family (e.g. kale, broccoli, watercress,&#xD;
             collard greens, kohlrabi, Brussels sprouts, mustard greens) and charbroiled meats for&#xD;
             at least 2 weeks before the Baseline Visit until the end of the study;&#xD;
&#xD;
         17. Inability to be venipunctured and/or tolerate venous access;&#xD;
&#xD;
         18. Subjects who are unable to read or speak English;&#xD;
&#xD;
         19. Any other sound medical reason as determined by the clinical Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>QPS Bio-Kinetic Clinical Applications</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>February 14, 2014</last_update_submitted>
  <last_update_submitted_qc>February 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rifampin,</keyword>
  <keyword>ketoconazole,</keyword>
  <keyword>CYP3A4,</keyword>
  <keyword>tasimelteon,</keyword>
  <keyword>VEC-162</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

